Skip to main content

Advertisement

SpringerLink
Log in

Reconsidering clinical pharmacology frameworks as a necessary strategy for improving the health care of patients: a systematic review

  • Point of View
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Breckenridge A, Dollery C, Rawlins M, Walport M (2006) The future of clinical pharmacology in the UK. Lancet 367(9516):1051

    Article  Google Scholar 

  2. Maxwell SR, Webb DJ (2006) Clinical pharmacology—too young to die? Lancet 367(9513):799–800

    Article  Google Scholar 

  3. Aronson JK (2010) Clinical pharmacology and therapeutics in the UK – a great instauration. Br J Clin Pharmacol 69(2):111–117

    Article  Google Scholar 

  4. Walport M, Foulkes I, Weissberg P, Morgan D, Nebhrajani S (2012) Medical research: no catch to UK charity funding. Nature 482(7385):308

    Article  CAS  Google Scholar 

  5. Zineh I, Woodcock J (2013) Clinical pharmacology and the catalysis of regulatory science: opportunities for the advancement of drug development and evaluation. Clin Pharmacol Ther 93(6):515–525

    Article  CAS  Google Scholar 

  6. Gaddum JH (1954) Clinical pharmacology. Proc R Soc Med 47(3):195–204

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Agoram BM (2008) Use of pharmacokinetic/ pharmacodynamic modelling for starting dose selection in first-in-human trials of high-risk biologics. Br J Clin Pharmacol 67(2):153–160

    Article  Google Scholar 

  8. Mavilio F (2017) Developing gene and cell therapies for rare diseases: an opportunity for synergy between academia and industry. Gene Ther 24(9):590–592

    Article  CAS  Google Scholar 

  9. Vezmar Kovačević S, Simišić M, Stojkov Rudinski S, Ćulafić M, Vučićević K, Prostran M, Miljković B (2014) Potentially inappropriate prescribing in older primary care patients. PLoS ONE 9(4):e95536

    Article  Google Scholar 

  10. Spinewine A, Schmader KE, Barber N, Hughes C, Lapane KL, Swine C, Hanlon JT (2007) Appropriate prescribing in elderly people: how well can it be measured and optimised? Lancet 370:173–184

    Article  Google Scholar 

  11. Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62(10):

    Article  Google Scholar 

  12. Martin JH, Henry D, Gray J et al (2016) Achieving the World Health Organization’s vision for clinical pharmacology. Br J Clin Pharmacol 81(2):223–227

    Article  Google Scholar 

  13. Thomson S, Figueras J, Evetovits T et al (2014) Economic crisis, health systems and health in Europe: impact and implications for policy. WHO Regional Office for Europe on behalf of the European Observatory on Health Systems and Policies. http://www.euro.who.int/en/about-us/partners/observatory/publications/studies/economic-crisis,-health-systems-and-health-in-europe.-impact-and-implications-for-policy-2015. Accessed 15 april 2017

  14. Allegaert K, Langhendries JP, van den Anker JN (2013) Educational paper: do we need neonatal clinical pharmacologists? Eur J Pediatr 172(4):429–435

    Article  Google Scholar 

  15. Kearns GL (2009) The pursuit of pediatric clinical pharmacology: perspectives from a current journey. J Pediatr Pharmacol Ther 14(1):10–16

    PubMed  PubMed Central  Google Scholar 

  16. Chen R, Snyder M (2012) Systems biology: personalized medicine for the future? Curr Opin Pharmacol 12(5):623–628

    Article  CAS  Google Scholar 

  17. Roger SD, Goldsmith D (2008) Biosimilars: it’s not as simple as cost alone. J Clin Pharm Ther 33:459–464

    Article  CAS  Google Scholar 

  18. Hawcutt DB, Russell NJ, Maqsood H et al (2016) Spontaneous adverse drug reaction reports for neonates and infants in the UK 2001-2010: content and utility analysis. Br J Clin Pharmacol 82(6):1601–1612

    Article  Google Scholar 

  19. Paul IM (2010) Advances in pediatric pharmacology, therapeutics, and toxicology. Adv Pediatr 57:163–183

    Article  Google Scholar 

  20. Birkett D, Brøsen K, Cascorbi I et al (2010) Clinical pharmacology in research, teaching and health care: considerations by IUPHAR, the International Union of Basic and Clinical Pharmacology. Basic Clin Pharmacol Toxicol 107(1):531–559

    Article  Google Scholar 

  21. Regulation (EU) No 1027/2012 of the European Parliament and of the Council of 25 October 2012 amending Regulation (EC) No 726/2004 as regards pharmacovigilance. Available at: https://publications.europa.eu/en/publication-detail/-/publication/c1ad51e2-2e32-11e2-ad46-01aa75ed71a1. Accessed 20 April 2017

  22. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 ("Clinical Trials Directive"). Available at: https://ec.europa.eu/health/human-use/clinical-trials/directive_en. Accessed 20 April 2017

  23. Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC. Available at: http://eur-lex.europa.eu Accessed 20 April 2017

  24. Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004. Available at: http://eur-lex.europa.eu. Accessed 20 April 2017

  25. Clinical Pharmacology in Health Care, Teaching and Research. Geneva: Council for the International Organizations of Medical Sciences; (2012). Available at: http://apps.who.int/medicinedocs/documents/s19916en/s19916en.pdf. Accessed 12 April 2017

Download references

Acknowledgements

The authors would like to acknowledge Professor David Webb and Doctor Lee Page of British Pharmacological Society, Professor Alexander Jetter of Klinik für Klinische Pharmakologie und Toxikologie, Zurich. The authors would also like to acknoweledge Omar Alexander for his contributions in the linguistic revising.

Contributors

DG and VAC were responsible for the study concept and design under the supervision of FS. The literature search, abstract screening, and data extraction were undertaken by DG with further confirmation by AC, GS and VAC. DG wrote the manuscript that was reviewed by AC. All the authors have read and approved the final manuscript submitted.

Funding

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Author information

Authors and Affiliations

  1. Department of Biotechnology and Translational Medicine, University of Milano, Milano, Italy

    Davide Grisafi

  2. Division of Clinical Pharmacology and Toxicology, Institute of Pharmacological Sciences of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland

    Alessandro Ceschi

  3. Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, Zurich, Switzerland

    Alessandro Ceschi

  4. Department of Life Sciences, University of Trieste, Trieste, Italy

    Gianni Sava

  5. Unit of Health Technology Assessment, Azienda Ospedaliera di Padova, Padova, Italy

    Veronica Avalos Clerici

  6. Department of Oncology and Hemato-oncology, Università of Milano, Milano, Italy

    Francesco Scaglione

Authors
  1. Davide Grisafi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alessandro Ceschi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gianni Sava
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Veronica Avalos Clerici
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Francesco Scaglione
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Davide Grisafi.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Electronic supplementary material

ESM 1

(DOCX 15 kb)

ESM 2

(DOCX 41 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Grisafi, D., Ceschi, A., Sava, G. et al. Reconsidering clinical pharmacology frameworks as a necessary strategy for improving the health care of patients: a systematic review. Eur J Clin Pharmacol 74, 1663–1670 (2018). https://doi.org/10.1007/s00228-018-2511-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-018-2511-8

Keywords

Search

Navigation